“TOZUDA came to my attention on LinkedIn as I have suffered a few concussions myself while playing football, hockey and downhill skiing in my past, said President, Scott Kadwell of RSK Medical Inc.. “I was also touched by the movie called “Concussion” depicting the findings of pathologist Dr. Bennett Omahu who brought the issue of brain damage to the forefront amongst NFL football players and the public domain. He discovered “Chronic Traumatic Encephalopathy” (CTE) in Pittsburgh Steeler players who had experienced repeated head blows which had terrible effects on their medical conditions and lifespan.

“It is easy for parents or coaches to assume players will not incur head injuries and some associations are afraid to acknowledge even the best protocols will not pick up all the head injuries due to the nature of the support and how hits impact people differently”. “Intentional or accidental hits are going to happen”. “It is important to have the “peace of mind” that the high impact hits will get checked out”. It is scientifically documented that 50% of head injuries go under diagnosed or undetected. In addition, 90% of diagnosed head injuries do not involve a loss of consciousness. Each additional hit is accumulative to causing further damage to the injured brain.

The TOZUDA Head Impact Sensor can be easily attached to hockey, snowboarding, snow-skiing, football, cycling and construction helmets to name a few. Please check out the www.tozuda.com website for further information or contact RSK Medical Inc. at generalinquiry@rskmedical.com

Please take note we also represent electroCore which manufactures a non-invasive Vagus Nerve Stimulator (nVNS) called the Sapphire for treatment of migraine and cluster headaches.

RSK Medical Inc. is pleased to announce a nationwide distribution agreement with Texray AB located in Kungsbacka, Sweden effective immediately.

Texray has invented the only radiation protection textile in the world.  Their unique material and product design can reduce scatter radiation towards the head and neck by up to 97% to enhance the safety of healthcare professionals.

The Texray product line can be used in interventional electrophysiology, cardiology, radiology and endovascular surgery procedures where RSK Medical already offers other specialty products.

We look forward to introducing the Texray radiation protection products across Canada.

It’s an absolute pleasure to share the news that gammaCore Sapphire now has the approval for adolescent migraine treatment in Canada. Specifically, our indication for use in Canada now reads;

gammaCore Sapphire (non-invasive vagus nerve stimulator) is indicated for:

• Preventive treatment of cluster headache in adult patients.
• Acute treatment of cluster headache in adult patients.

And now!

• Preventive treatment of migraine headache in adolescent (age 12 and older) and adult patients.
• Acute treatment of migraine headache in adolescent (age 12 and older) and adult patients.

RSK Medical Inc. is pleased to announce a new nationwide distribution agreement with ProCell Surgical Inc. effective October 1st/2021. The ProCell device is a patient blood management system device used during surgical procedures requiring intraoperative autotransfusions. Their unique blood management system enhances a hospital’s surgical blood conservation efforts during surgery and provides added safety to the patient by utilizing their own blood vs. transfusions.

The ProCell has potential use in trauma, cardiac, vascular, transplant and orthopaedic surgical procedures. This product nicely complements RSK Medical current product portfolio serving these specialty surgical areas.

We look forward to introducing the unique and cost-effective ProCell technology across Canada.

ST. PAUL, Minn.–(BUSINESS WIRE)– Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Canada have been treated with its Diamondback 360®Coronary Orbital Atherectomy System (OAS).

The first patients in Canada were treated by Sanjog Kalra, MD, Interventional Cardiologist and Cardiac Critical Care Physician at the Peter Munk Cardiac Centre, Toronto General Hospital, part of the University Health Network.

Read more.

“What is it? The gammaCore Sapphire^TM (nVNS)  is a hand-held device that the patient uses to stimulate the vagus nerve in the neck.  The vagus nerve is an important highway of communication between the body and the brain and plays an important role in regulating pain.”

Read more.

RSK Medical Inc. ships first electroCore gamma Sapphire non-invasive vagal nerve stimulation systems (nVNS) for primary headache prevention and treatment (cluster and migraine). Order/authorization forms signed by a Canadian medical licenced physician are required before shipment. Please see www.gammacoreCanada.com for further information.

RSK Medical Inc. and Cardiovascular Systems Inc.(CSI), manufacturers of the proven Diamondback 360 orbital rotational atherectomy systems for peripheral and coronary use have signed an agent representation agreement for sales, marketing and clinical support across Canada. The Diamondback 360 offers a low profile (6Fr compatible) system for the radial or femoral approach. The system has a unique mechanism of action (MOA) using a combination of centrifugal force and differential sanding to safely and simply reduce arterial calcium to enable successful stent delivery. The two platforms have been fully approved by Health Canada and we look forward to launching Diamondback 360 over the next few months. Please see www.csi360.com for further product details and clinical data.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in Canada for prevention and therapeutic treatment of migraine and cluster headache, as outlined in the registration application with Health Canada.

gammaCore Sapphire will be distributed in Canada by RSK Medical Inc., pursuant to an exclusive distribution agreement announced on January 26, 2021. The initial term of the agreement is three years, and the agreement contains customary terms and conditions, including minimum purchase commitments. “Patients and clinicians in Canada have been waiting years for this novel migraine and cluster headache therapy. RSK Medical Inc. is delighted to bring another breakthrough medical device technology to the Canadian marketplace. We look forward to working towards provincial healthcare funding for this patient group” said Scott Kadwell, President of RSK Medical Inc.

“Migraine Canada is pleased to learn that a new device to treat migraine and cluster headaches has been approved by Health Canada. Timely and equitable access to diverse and affordable treatment options and devices are essential for patients living with these painful and debilitating diseases” said Dr. Elizabeth Leroux, president of the Canadian Headache Society and the founder and chair of Migraine Canada.

RSK Medical Inc. has signed a long term agreement (Canada-wide) to represent Angiodroid Srl from Bologna, Italy.

Angiodroid manufacturers The CO2 Injector, the first system for Automated Carbon Dioxide Angiography (ACDA) dedicated to diagnostic and interventional procedures in peripheral and venous systems.

The Safety and Efficacy of Angiodroid’s CO2 injector has been validated in over 20 international clinical studies to date. This technology makes it possible to use CO2, a 100% biocompatible gas to obtain high quality radiological angiographic images while preserving the renal function of the patients. The ACDA system system avoids all contrast induced nephropathy risks and potential for allergic reactions.

Angiodroid has begun preparation for submitting for Health Canada regulatory approval. Find more on www.angiodroid.com.